Your browser doesn't support javascript.
loading
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.
Grams, Morgan E; Coresh, Josef; Matsushita, Kunihiro; Ballew, Shoshana H; Sang, Yingying; Surapaneni, Aditya; Alencar de Pinho, Natalia; Anderson, Amanda; Appel, Lawrence J; Ärnlöv, Johan; Azizi, Fereidoun; Bansal, Nisha; Bell, Samira; Bilo, Henk J G; Brunskill, Nigel J; Carrero, Juan J; Chadban, Steve; Chalmers, John; Chen, Jing; Ciemins, Elizabeth; Cirillo, Massimo; Ebert, Natalie; Evans, Marie; Ferreiro, Alejandro; Fu, Edouard L; Fukagawa, Masafumi; Green, Jamie A; Gutierrez, Orlando M; Herrington, William G; Hwang, Shih-Jen; Inker, Lesley A; Iseki, Kunitoshi; Jafar, Tazeen; Jassal, Simerjot K; Jha, Vivekanand; Kadota, Aya; Katz, Ronit; Köttgen, Anna; Konta, Tsuneo; Kronenberg, Florian; Lee, Brian J; Lees, Jennifer; Levin, Adeera; Looker, Helen C; Major, Rupert; Melzer Cohen, Cheli; Mieno, Makiko; Miyazaki, Mariko; Moranne, Olivier; Muraki, Isao.
Afiliación
  • Grams ME; Division of Precision Medicine, Department of Medicine, Grossman School of Medicine, New York University, New York, New York.
  • Coresh J; Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
  • Matsushita K; Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
  • Ballew SH; Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
  • Sang Y; Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
  • Surapaneni A; Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
  • Alencar de Pinho N; Division of Precision Medicine, Department of Medicine, Grossman School of Medicine, New York University, New York, New York.
  • Anderson A; Centre for Research in Epidemiology and Population Health, Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.
  • Appel LJ; School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana.
  • Ärnlöv J; Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
  • Azizi F; School of Health and Social Studies, Dalarna University, Falun, Sweden.
  • Bansal N; Department of Neurobiology, Care Sciences, and Society, Family Medicine and Primary Care Unit, Karolinska Institutet, Huddinge, Sweden.
  • Bell S; Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Bilo HJG; Division of Nephrology, University of Washington, Seattle.
  • Brunskill NJ; Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, Scotland.
  • Carrero JJ; Diabetes Centre and Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Chadban S; Department of Cardiovascular Sciences, University of Leicester, and John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, England.
  • Chalmers J; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, and Department of Clinical Science, Danderyd Hospital, Stockholm, Sweden.
  • Chen J; Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia.
  • Ciemins E; George Institute for Global Health, University of New South Wales, Sydney, Australia.
  • Cirillo M; School of Public Health, Imperial College, London, England.
  • Ebert N; Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.
  • Evans M; Department of Medicine, School of Medicine, Tulane University, New Orleans, Louisiana.
  • Ferreiro A; AMGA (American Medical Group Association), Alexandria, Virginia.
  • Fu EL; Department Scuola Medica Salernitana, University of Salerno, Fisciano, Italy.
  • Fukagawa M; Institute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Green JA; Department of Renal Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Gutierrez OM; Departamento de Nefrología, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
  • Herrington WG; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Hwang SJ; Division of Nephrology, Endocrinology, and Metabolism, School of Medicine, Tokai University, Isehara, Japan.
  • Inker LA; Department of Nephrology, Geisinger Commonwealth School of Medicine, Danville, Pennsylvania.
  • Iseki K; Center for Kidney Health Research, Geisinger, Danville, Pennsylvania.
  • Jafar T; Division of Nephrology, University of Alabama at Birmingham.
  • Jassal SK; Medical Research Council Population Health Research Unit, University of Oxford, Oxford, England.
  • Jha V; Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, England.
  • Kadota A; Framingham Heart Study, Framingham, Massachusetts.
  • Katz R; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
  • Köttgen A; Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.
  • Konta T; Okinawa Heart and Renal Association, Okinawa, Japan.
  • Kronenberg F; Programme in Health Services and Systems Research, Duke-NUS Medical School, Singapore.
  • Lee BJ; Duke Global Health Institute, Duke University, Durham, North Carolina.
  • Lees J; University of California-San Diego, La Jolla.
  • Levin A; San Diego VA Health Care System, San Diego, California.
  • Looker HC; George Institute for Global Health India, New Delhi, India.
  • Major R; George Institute for Global Health, School of Public Health, Imperial College, London, England.
  • Melzer Cohen C; Department of Public Health, NCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan.
  • Mieno M; Department of Obstetrics and Gynecology, University of Washington, Seattle.
  • Miyazaki M; Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
  • Moranne O; Department of Public Health and Hygiene, Yamagata University Faculty of Medicine, Yamagata, Japan.
  • Muraki I; Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria.
JAMA ; 330(13): 1266-1277, 2023 10 03.
Article en En | MEDLINE | ID: mdl-37787795
ABSTRACT
Importance Chronic kidney disease (low estimated glomerular filtration rate [eGFR] or albuminuria) affects approximately 14% of adults in the US.

Objective:

To evaluate associations of lower eGFR based on creatinine alone, lower eGFR based on creatinine combined with cystatin C, and more severe albuminuria with adverse kidney outcomes, cardiovascular outcomes, and other health outcomes. Design, Setting, and

Participants:

Individual-participant data meta-analysis of 27 503 140 individuals from 114 global cohorts (eGFR based on creatinine alone) and 720 736 individuals from 20 cohorts (eGFR based on creatinine and cystatin C) and 9 067 753 individuals from 114 cohorts (albuminuria) from 1980 to 2021. Exposures The Chronic Kidney Disease Epidemiology Collaboration 2021 equations for eGFR based on creatinine alone and eGFR based on creatinine and cystatin C; and albuminuria estimated as urine albumin to creatinine ratio (UACR). Main Outcomes and

Measures:

The risk of kidney failure requiring replacement therapy, all-cause mortality, cardiovascular mortality, acute kidney injury, any hospitalization, coronary heart disease, stroke, heart failure, atrial fibrillation, and peripheral artery disease. The analyses were performed within each cohort and summarized with random-effects meta-analyses.

Results:

Within the population using eGFR based on creatinine alone (mean age, 54 years [SD, 17 years]; 51% were women; mean follow-up time, 4.8 years [SD, 3.3 years]), the mean eGFR was 90 mL/min/1.73 m2 (SD, 22 mL/min/1.73 m2) and the median UACR was 11 mg/g (IQR, 8-16 mg/g). Within the population using eGFR based on creatinine and cystatin C (mean age, 59 years [SD, 12 years]; 53% were women; mean follow-up time, 10.8 years [SD, 4.1 years]), the mean eGFR was 88 mL/min/1.73 m2 (SD, 22 mL/min/1.73 m2) and the median UACR was 9 mg/g (IQR, 6-18 mg/g). Lower eGFR (whether based on creatinine alone or based on creatinine and cystatin C) and higher UACR were each significantly associated with higher risk for each of the 10 adverse outcomes, including those in the mildest categories of chronic kidney disease. For example, among people with a UACR less than 10 mg/g, an eGFR of 45 to 59 mL/min/1.73 m2 based on creatinine alone was associated with significantly higher hospitalization rates compared with an eGFR of 90 to 104 mL/min/1.73 m2 (adjusted hazard ratio, 1.3 [95% CI, 1.2-1.3]; 161 vs 79 events per 1000 person-years; excess absolute risk, 22 events per 1000 person-years [95% CI, 19-25 events per 1000 person-years]). Conclusions and Relevance In this retrospective analysis of 114 cohorts, lower eGFR based on creatinine alone, lower eGFR based on creatinine and cystatin C, and more severe UACR were each associated with increased rates of 10 adverse outcomes, including adverse kidney outcomes, cardiovascular diseases, and hospitalizations.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Creatinina / Albúminas / Albuminuria / Insuficiencia Renal Crónica / Cistatina C / Tasa de Filtración Glomerular Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Creatinina / Albúminas / Albuminuria / Insuficiencia Renal Crónica / Cistatina C / Tasa de Filtración Glomerular Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Año: 2023 Tipo del documento: Article